# A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

> **NCT07713459** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Kure Cells, INC** · enrollment: 105 (estimated)

## Conditions studied

- Lymphoma Nonhodgkin
- Marginal Zone B Cell Lymphoma
- Diffuse Large B Cell Lymphoma (DLBCL)
- Follicular B-cell Non-Hodgkin's Lymphoma
- CAR T Cell Therapy

## Interventions

- **BIOLOGICAL:** CART Infusion

## Key facts

- **NCT ID:** NCT07713459
- **Lead sponsor:** Kure Cells, INC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2029-08-31
- **Final completion:** 2029-11-30
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07713459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07713459, "A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07713459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*